Julius Baer International is aiming to expand its presence in the UK market, with the launch of its Biotech fund.
Managed by Eric Bernhardt and Nathalie Flury, the fund targets global biotech companies which develop products and technology for the healthcare, agricultural, food science and environmental sectors.
The company believes its time is ripe to invest in the biotech industry, as the majority of biotech companies will continue to show promising earnings growth.
“Despite the economic downturn biotech earnings expectations remain high. The industry has seen strong M&A activity, strengthening pipelines and revenue growth, and valuations remain attractive,” says Eric Bernhardt.
L.D.